As the DIDB content continues to expand, we are pleased to announce that post-marketing requirements and post-marketing commitments (PMRs and PMCs) for drugs approved by the FDA in 2014, 2015, and 2016 have now been entered in the DIDB. The DDI, hepatic impairment, and renal impairment results can be found under the drug’s original NDA or BLA numbers. Updated label recommendations are also presented in the drug DDI Summary.
Having access to this additional information is key to fully understand the DDI profile of NMEs, and the DIDB Editorial Team is now working on PMR/PMC data for drugs approved in 2017 and 2018.
As always, feel free to contact us at DIDBase@certara.com if you have any questions or comments.